A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC

A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC

Abstract Immune checkpoint inhibitors (ICIs) have become a vital part of the therapeutic landscape for non‐small cell lung cancer (NSCLC) in recent years benefiting from their remarkable efficacy. However, ICIs are associated with potentially life‐threatening immune‐related adverse events (irAEs). T...

Full description

Bibliographic Details
Main Authors: Renwei Zhang, Daming Kong, Rong Chen, Yuchen Guo, Weizhe Jian, Mengyi Han, Tianyan Zhou
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12834

Internet

https://doi.org/10.1002/psp4.12834

Similar Items